文献速递心脑血管急症重症综合管理与镇静镇痛

美国缺血性卒中住院患者在COVID-19疫情前与疫情期间的特征及结局比较

Characteristics and Outcomes Among US Patients Hospitalized for Ischemic Stroke Before vs During the COVID-19 Pandemic.
PubMed 文献 · JAMA Netw Open · 2021-05-03
一句话结论2020年4月美国缺血性卒中出院量降至10 846例后于7月恢复至疫情前水平;合并COVID-19的缺血性卒中患者院内死亡风险显著升高(校正OR 5.17)。

这项回顾性队列研究利用Vizient临床数据库,纳入2019年1月1日至2020年12月31日美国43个州478家非联邦医院中非择期入院、入院时未接受临终关怀的缺血性卒中患者282 847例,比较2019年对照组与2020年4–12月出院的非COVID-19组和COVID-19组的特征与结局。2020年4月出院量降至10 846例,7月恢复至13 639例;合并COVID-19者中黑人和西班牙裔占比更高,糖尿病、肥胖、急性冠脉综合征、肺栓塞及需插管比例更高。校正基线因素后,合并COVID-19的缺血性卒中患者院内死亡风险显著高于2019年对照组(校正OR 5.17,95%CI 4.83–5.53;进一步校正NIHSS后校正OR 3.57,95%CI 3.15–4.05)。

要点

  • 合并COVID-19的缺血性卒中患者院内死亡风险显著高于2019年对照组:校正OR 5.17(95%CI 4.83–5.53),进一步校正NIHSS后校正OR 3.57(95%CI 3.15–4.05)。
  • 2020年4月缺血性卒中出院量降至10 846例,7月恢复至疫情前水平13 639例;2020年其余月份月均出院13 492例(SD 554)。
  • 合并COVID-19的缺血性卒中患者中黑人和西班牙裔分别占27.5%和16.0%,高于2019年缺血性卒中出院者的21.4%和7.0%。
  • 合并COVID-19组需插管比例37.6%,高于非COVID-19组的12.3%和2019年对照组的11.3%。
  • 合并COVID-19组糖尿病(53.0%)、肥胖(24.5%)、急性冠脉综合征(15.8%)、肺栓塞(6.8%)比例均高于非COVID-19组和2019年对照组。

适用人群与场景

  • 美国43个州478家非联邦医院中非择期入院的缺血性卒中患者,入院时未接受临终关怀。
  • 排除2020年1–3月出院的41 166例(COVID-19状态数据不可靠),最终纳入282 847例。
  • 2019年出院者165 912例为对照组;2020年4–12月出院者116 935例,其中非COVID-19组111 418例(95.3%),COVID-19组5517例(4.7%)。

研究设计与关键结果

  • 研究类型:回顾性队列研究,使用Vizient临床数据库,覆盖美国43个州478家非联邦医院,纳入282 847例缺血性卒中患者。
  • 出院量变化:2019年月均出院13 846例(SD 553);2020年2月起下降,4月降至最低10 846例,7月恢复至13 639例;2020年其余月份月均13 492例(SD 554)。
  • 人群构成:对照组50.7%男性、63.4%白人、26.3%年龄≥80岁;非COVID-19组51.9%男性、62.8%白人、24.6%年龄≥80岁;COVID-19组58.0%男性、42.5%白人、21.3%年龄≥80岁。
  • 种族分布:2019年黑人和西班牙裔分别占缺血性卒中出院者的21.4%和7.0%,2020年合并COVID-19者中分别占27.5%和16.0%。
  • 合并症比较(对照组 vs 非COVID-19组 vs COVID-19组):吸烟16.0% vs 17.2% vs 6.4%;高血压73.0% vs 73.1% vs 68.2%;血脂异常61.2% vs 63.2% vs 56.6%;糖尿病39.8% vs 40.5% vs 53.0%;肥胖16.2% vs 18.4% vs 24.5%;急性冠脉综合征8.0% vs 9.2% vs 15.8%;肺栓塞1.9% vs 2.4% vs 6.8%;需插管11.3% vs 12.3% vs 37.6%。
  • 主要终点:校正基线因素后,合并COVID-19的缺血性卒中患者院内死亡风险高于2019年对照组(校正OR 5.17,95%CI 4.83–5.53);进一步校正NIHSS后校正OR 3.57(95%CI 3.15–4.05)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 疫情期间缺血性卒中出院量一度下降后于2020年7月恢复至疫情前水平,合并COVID-19者病死率高、合并症负担重,尤其黑人和西班牙裔人群。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: After the emergence of COVID-19, studies reported a decrease in hospitalizations of patients with ischemic stroke (IS), but there are little to no data regarding hospitalizations for the remainder of 2020, including outcome data from a large cohort of patients with IS and comorbid COVID-19.

OBJECTIVE: To assess hospital discharge rates, demographic factors, and outcomes of hospitalization associated with the COVID-19 pandemic among US patients with IS before vs during the COVID-19 pandemic.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used data from the Vizient Clinical Data Base on 324 013 patients with IS at 478 nonfederal hospitals in 43 US states between January 1, 2019, and December 31, 2020. Patients were eligible if they were admitted to the hospital on a nonelective basis and were not receiving hospice care at the time of admission. A total of 41 166 discharged between January and March 2020 were excluded from the analysis because they had unreliable data on COVID-19 status, leaving 282 847 patients for the study.

EXPOSURE: Ischemic stroke and laboratory-confirmed COVID-19.

MAIN OUTCOMES AND MEASURES: Monthly counts of discharges among patients with IS in 2020. Demographic characteristics and outcomes, including in-hospital death, among patients with IS who were discharged in 2019 (control group) were compared with those of patients with IS with or without comorbid COVID-19 (COVID-19 and non-COVID-19 groups, respectively) who were discharged between April and December 2020.

RESULTS: Of the 282 847 patients included in the study, 165 912 (50.7% male; 63.4% White; 26.3% aged ≥80 years) were allocated to the control group; 111 418 of 116 935 patients (95.3%; 51.9% male; 62.8% White; 24.6% aged ≥80 years) were allocated to the non-COVID-19 group and 5517 of 116 935 patients (4.7%; 58.0% male; 42.5% White; 21.3% aged ≥80 years) to the COVID-19 group. A mean (SD) of 13 846 (553) discharges per month among patients with IS was reported in 2019. Discharges began decreasing in February 2020, reaching a low of 10 846 patients in April 2020 before returning to a prepandemic level of 13 639 patients by July 2020. A mean (SD) of 13 492 (554) discharges per month was recorded for the remainder of 2020. Black and Hispanic patients accounted for 21.4% and 7.0% of IS discharges in 2019, respectively, but accounted for 27.5% and 16.0% of those discharged with IS and comorbid COVID-19 in 2020. Compared with patients in the control and non-COVID-19 groups, those in the COVID-19 group were less likely to smoke (16.0% vs 17.2% vs 6.4%, respectively) and to have hypertension (73.0% vs 73.1% vs 68.2%) or dyslipidemia (61.2% vs 63.2% vs 56.6%) but were more likely to have diabetes (39.8% vs 40.5% vs 53.0%), obesity (16.2% vs 18.4% vs 24.5%), acute coronary syndrome (8.0% vs 9.2% vs 15.8%), or pulmonary embolus (1.9% vs 2.4% vs 6.8%) and to require intubation (11.3% vs 12.3% vs 37.6%). After adjusting for baseline factors, patients with IS and COVID-19 were more likely to die in the hospital than were patients with IS in 2019 (adjusted odds ratio, 5.17; 95% CI, 4.83-5.53; National Institutes of Health Stroke Scale adjusted odds ratio, 3.57; 95% CI, 3.15-4.05).

CONCLUSIONS AND RELEVANCE: In this cohort study, after the emergence of COVID-19, hospital discharges of patients with IS decreased in the US but returned to prepandemic levels by July 2020. Among patients with IS between April and December 2020, comorbid COVID-19 was relatively common, particularly among Black and Hispanic populations, and morbidity was high.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. de Havenon A, Ney JP, Callaghan B, et al. Characteristics and Outcomes Among US Patients Hospitalized for Ischemic Stroke Before vs During the COVID-19 Pandemic. JAMA Netw Open. 2021. PMID: 33999162. doi:10.1001/jamanetworkopen.2021.10314

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。